此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

超选择性动脉内重复输注西妥昔单抗治疗初诊胶质母细胞瘤

2026年11月11日 更新者:John Boockvar, MD Zucker SOM @Hofstra/Northwell、Northwell Health

超选择性动脉内重复输注西妥昔单抗治疗初诊胶质母细胞瘤的I/II期试验

Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression EFGR (Epidermal Growth Factor Receptor) which is blocked by Cetuximab (CTX). The investigators have recently completed a separate Phase I clinical trial using superselective intra-arterial cerebral infusion (SIACI) of CTX after blood brain barrier disruption (BBBD) for recurrent GBM (Chakraborty et al, in revision, Journal of Neurooncology). The investigators found that intra-arterial infusion of CTX is well tolerated with few adverse effects. The investigators hypothesize that in patients with newly diagnosed GBM, repeated SIACI of this drug after BBBD will be safe and efficacious for our patients when combined with standard chemoradiation (STUPP protocol).

This trial will be a non-randomized open label Phase I/II clinical trial. In addition to standard chemotherapy and radiation therapy (STUPP protocol) the patient will be given CTX intra-arterially after BBBD for a total of three doses at approximately post surgery days 30, 120 and 210.

研究概览

研究类型

介入性

注册 (估计的)

33

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • New York
      • New York、New York、美国、10075
        • 招聘中
        • Lenox Hill Brain Tumor Center
        • 接触:
        • 接触:
        • 副研究员:
          • David Langer, MD
        • 副研究员:
          • Christopher Filippi, MD
        • 副研究员:
          • Tamika Wong, MPH
        • 副研究员:
          • Rafael Ortiz, MD
        • 副研究员:
          • Ashley Ray, NP
        • 副研究员:
          • Sherese Fralin, NP
        • 副研究员:
          • Anuj Goenka, MD
        • 副研究员:
          • Jed Pollack, MD
        • 副研究员:
          • Karissa Tan, NP
        • 副研究员:
          • Shamik Chakraborty, MD
        • 首席研究员:
          • John Boockvar, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female patients of ≥18 years of age.

  • Patients with a documented histologic diagnosis of newly diagnosed glioblastoma multiforme (GBM)

  • Patients with pathology confirmed histologic EGFR overexpression

  • Patients must have at least one confirmed and evaluable tumor site.∗

    *A confirmed tumor site is one in which is biopsy-proven. NOTE: Radiographic procedures (e.g., Gd-enhanced MRI or CT scans) documenting existing lesions must have been performed within two weeks of treatment on this research study.

  • Patients must have a Karnofsky performance status ≥70% (or the equivalent ECOG level of 0-2) and an expected survival of ≥ three months.

  • No chemotherapy for two weeks prior to treatment under this research protocol and no external beam radiation for eight weeks prior to treatment under this research protocol.

  • Patients must have adequate hematologic reserve with WBC≥3000/mm3, absolute neutrophils ≥1500/mm3 and platelets ≥100,000/ mm3. Patients who are on Coumadin must have a platelet count of ≥150,000/ mm3

  • Pre-enrollment chemistry parameters must show: bilirubin<1.5X the institutional upper limit of normal (IUNL); AST or ALT<2.5X IUNL and creatinine<1.5X IUNL.

  • Pre-enrollment coagulation parameters (PT and PTT) must be ≤1.5X the IUNL.

  • Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study.

  • Patients must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening.

Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Women of childbearing potential and fertile men will be informed as to the potential risk of conception while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period.
  • Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring
  • Patients with radiological evidence of leptomeningeal disease.
  • Patients with history of allergic reaction to CTX
  • Patients who initiated or completed chemo/RT

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Intra-arterial Cetuximab after BBBD

Mannitol 20% 12.5ml over two minutes for Blood Brain Barrier (BBB) disruption followed by CTX administered intra-arterially for three doses at a dose of 250mg/m2

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression Free Survival (PFS)
大体时间:6 months

The 6-month PFS will be estimated by calculating the proportion of patients who are alive at 6 months from treatment commencement and are progression-free.

6 months
Overall Survival (OS)
大体时间:2 years

OS will be calculated as the time from treatment initiation to the date of death.

2 years

次要结果测量

结果测量
措施说明
大体时间
Composite overall response rate (CORR) through the Response Assessment in Neuro-Oncology (RANO)
大体时间:6 months

Subjects will be classified according to the RANO criteria, which is a composite of MRI changes, clinical response and changes in steroid use.

6 months
Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03
大体时间:6 months

Toxicities will be tabulated and graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03

6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2016年10月11日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2029年12月1日

研究注册日期

首次提交

2016年8月5日

首先提交符合 QC 标准的

2016年8月5日

首次发布 (估计的)

2016年8月10日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅